Literature DB >> 21265801

Terminal monosaccharide expression on amniotic glycoproteins as biomarkers of fetus maturity.

Magdalena Orczyk-Pawiłowicz1, Iwona Kątnik-Prastowska.   

Abstract

Glycotypes, particularly those that terminate with sialic acid and fucose are known to play a fundamental role in human development, during implantation, growth and differentiation of fetal tissues. The present review describes changes in the exposition of terminal sialic acid and fucose isoforms in the amniotic fluid glycoconjugates, α1-acid glycoprotein and fibronectin during critical stages of pregnancy, i.e. second and third trimester, perinatal period, delivery and post-date pregnancy. The distinct amniotic glycoforms are suggested to be implicated in regulatory processes to ensure homoeostasis during pregnancy and to protect the fetus. These may have the potential of becoming additional laboratory makers in obstetrics to monitor pregnancy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21265801     DOI: 10.1042/BST0390344

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  3 in total

1.  Lactation stage-related expression of sialylated and fucosylated glycotopes of human milk α-1-acid glycoprotein.

Authors:  Magdalena Orczyk-Pawiłowicz; Lidia Hirnle; Marta Berghausen-Mazur; Iwona M Kątnik-Prastowska
Journal:  Breastfeed Med       Date:  2014-06-03       Impact factor: 1.817

2.  Lectin-based analysis of fucose and sialic acid expressions on human amniotic IgA during normal pregnancy.

Authors:  Magdalena Orczyk-Pawiłowicz; Daria Augustyniak; Lidia Hirnle; Iwona Kątnik-Prastowska
Journal:  Glycoconj J       Date:  2012-12-19       Impact factor: 2.916

3.  Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer.

Authors:  Jung-Mo Ahn; Hye-Jin Sung; Yeon-Hee Yoon; Byung-Gyu Kim; Won Suk Yang; Cheolju Lee; Hae-Min Park; Bum-Jin Kim; Byung-Gee Kim; Soo-Youn Lee; Hyun-Joo An; Je-Yoel Cho
Journal:  Mol Cell Proteomics       Date:  2013-10-01       Impact factor: 5.911

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.